Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization

Tyler J. Gluckman, Jodi B. Segal, Natalie L. Fredde, Kenneth E. Saland, Jayesh T. Jani, Jeanine M. Walenga, M. Margaret Prechel, Kathleen M. Citro, David A. Zidar, Emily Fox, Steven P. Schulman, Thomas S. Kickler, Jeffrey J. Rade

Research output: Contribution to journalArticle

Abstract

The incidence of antiplatelet factor-4/heparin antibody formation in patients who receive contemporary doses of unfractionated heparin in the setting of percutaneous coronary revascularization is unknown. Also unknown is the ability of these antibodies to activate platelets or adversely affect clinical outcome in the absence of clinically recognized heparin-induced thrombocytopenia. To address these questions, we serially measured antiplatelet factor-4/heparin antibody levels and performed serotonin release assays in patients who underwent percutaneous coronary intervention. Correlations were then made across antibody induction, heparin exposure, and clinical outcome at 6 months.

Original languageEnglish (US)
Pages (from-to)744-747
Number of pages4
JournalAmerican Journal of Cardiology
Volume95
Issue number6
DOIs
StatePublished - Mar 15 2005

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization'. Together they form a unique fingerprint.

  • Cite this

    Gluckman, T. J., Segal, J. B., Fredde, N. L., Saland, K. E., Jani, J. T., Walenga, J. M., Prechel, M. M., Citro, K. M., Zidar, D. A., Fox, E., Schulman, S. P., Kickler, T. S., & Rade, J. J. (2005). Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization. American Journal of Cardiology, 95(6), 744-747. https://doi.org/10.1016/j.amjcard.2004.11.026